Phase III Clinical Trial of DA-5212 in Patients With Functional Dyspepsia

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate efficacy and safety of DA-5212 in patients with functional dyspepsia

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A ST Co., Ltd.

Criteria

Inclusion Criteria:

• Men or women ≥ 19 years of age

• Patients who diagnosed with functional dyspepsia

• Patients with no organic cause for digestive symptoms found by upper gastrointestinal endoscopy at screening visit

Exclusion Criteria:

• Patients with organic disease or medical history that may cause dyspepsia within 6 months before screening visit

• Patients who have a history of drugs or alcohol abuse and dependence within 6 months before screening visit

• Patients with hypersensitivity to investigational drugs and similar drugs

• Pregnant or breastfeeding women